A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (SA-AKI)
Latest Information Update: 13 Jun 2025
At a glance
- Drugs TIN 816 (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms SA-AKI
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 14 Aug 2024 Planned End Date changed from 30 Mar 2026 to 20 Feb 2026.
- 14 Aug 2024 Planned primary completion date changed from 9 Jan 2026 to 4 Dec 2025.
- 23 Apr 2024 Planned End Date changed from 16 Feb 2026 to 30 Mar 2026.